Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Stamford; Andrew
Address:
Chatham Township, NJ
No. of patents:
22
Patents:












Patent Number Title Of Patent Date Issued
8278334 Cyclic amine BACE-1 inhibitors having a benzamide substituent October 2, 2012
Disclosed are compounds of the formula ##STR00001## or a pharmaceutically acceptable salt or solvate thereof, wherein R.sup.1 is ##STR00002## R is --C(O)--N(R.sup.27)(R.sup.28) or ##STR00003## and the remaining variables are as defined in the specification. Also disclose
8183252 Heterocyclic aspartyl protease inhibitors May 22, 2012
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.s
8168641 Aspartyl protease inhibitors May 1, 2012
Disclosed are compounds of formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, U, W, X, R.sup.1, R.sup.2, R.sup.6, R.sup.7, R.sup.30 and R.sup.31 are as described above in the specification. Also disclosed is the method of inh
8110682 Preparation and use of compounds as aspartyl protease inhibitors February 7, 2012
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein A is a bond, --C(O)--, or --C(R.sup.3')(R.sup.4')--; X is --N(R.sup.1)-- or --C(R.sup.6)(R.sup.7)--; Y is --S(O).sub.2--, --C(.dbd.O)
8093254 Aspartyl protease inhibitors January 10, 2012
Disclosed are compounds of formula I (Chemical formula should be inserted here as it appears on abstract in paper form) Formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.14, V, W, X, Y, Z,
7973067 Heterocyclic aspartyl protease inhibitors July 5, 2011
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.s
7910590 Cyclic amine bace-1 inhibitors having a heterocyclic substituent March 22, 2011
Disclosed are novel compounds of the formula ##STR00001## or a pharmaceutically acceptable salt or solvate thereof, wherein R.sup.1 is ##STR00002## X is --O--, --C(R .sup.14).sub.2-- or --N(R)--; Z is --C(R.sup.14).sub.2-- or --N(R)--; t is 0, 1, 2 or 3; each R and R.sup.2 is
7868000 Aspartyl protease inhibitors January 11, 2011
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein j, k, U, W, R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7 and R.sup.7a are as described above in the specification.Also disclosed
7812013 Macrocyclic heterocyclic aspartyl protease inhibitors October 12, 2010
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt, solvate or ester thereof, wherein U, W, X, L, Y, M, Z, c, d, e, f, g, h, s, t, R.sup.1, R.sup.2, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13,
7763609 Heterocyclic aspartyl protease inhibitors July 27, 2010
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.sup.5)
7759354 Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof July 20, 2010
The present application provides compounds of the Formula: ##STR00001## and stereoisomers, tautomers, or pharmaceutically acceptable salts and solvates thereof, wherein U, W, R, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 in each formula (when present) are as defined in the specification, and
7759353 Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods July 20, 2010
Disclosed are certain substituted spiro iminopyrimidinones and other compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein U, W, A, R, R.sup.1, R.sup.2, R.sup.6a and R.sup.7, are as defined in the specifi
7713985 Adenosine A.sub.a2 receptor antagonists May 11, 2010
Compounds having the structural formula I ##STR00001## or a pharmaceutically acceptable salt thereof, wherein: X.sup.1 and X.sup.2 are 1-3 substituents independently selected from the group consisting of H, alkyl, halo, --CF.sub.3, --OCF.sub.3, alkoxy, --OH and --CN; n is 0, 1 or
7709492 Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A.sub.2a receptor antagonists May 4, 2010
Compounds having the structural formula I ##STR00001## or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are H,
7700603 Heterocyclic aspartyl protease inhibitors April 20, 2010
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.sup.5)
7662816 Cyclic amine BACE-1 inhibitors having a benzamide substituent February 16, 2010
Disclosed are compounds of the formula ##STR00001## or a pharmaceutically acceptable salt or solvate thereof, wherein R.sup.1 is ##STR00002## R is --C(O)--N(R.sup.27)(R.sup.28) or ##STR00003## and the remaining variables are as defined in the specification.Also disclosed are
7598250 Cyclic amine BACE-1 inhibitors having a heterocyclic substituent October 6, 2009
Disclosed are novel compounds of the formula ##STR00001## or a pharmaceutically acceptable salt or solvate thereof, wherein R.sup.1 is ##STR00002## X is --O--, --C(R.sup.14).sub.2-- or --N(R)--; Z is --C(R.sup.14).sub.2-- or --N(R)--; t is 0, 1, 2 or 3; each R and R.sup.2 is
7592348 Heterocyclic aspartyl protease inhibitors September 22, 2009
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.sup.5)
7368449 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A.sub. May 6, 2008
Compounds having the structural formula I ##STR00001## or a pharmaceutically acceptable salt thereof, wherein R is ##STR00002## R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are H, alkyl or alkoxyalkyl; R.sup.6 is H, alkyl, hydroxyalkyl or --CH.sub.2F; R.sup.7, R.sup.8 and R.s
7312223 Metabolite of xanthine Phosphodiesterase 5 inhibitor and derivatives thereof useful for treatmen December 25, 2007
The present invention is directed to a metabolite of a xanthine Phosphodiesterase type 5 inhibitor having the following structure ##STR00001## derivatives, and formulations thereof, and processes for preparing the same.Further disclosed are methods of treating a physiological disord
7268141 Xanthine phosphodiesterase V inhibitors September 11, 2007
A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders: ##STR00001## For example, a representative compound of the inve
6897217 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a recepto May 24, 2005
Compounds having the structural formula I ##STR1##or a pharmaceutically acceptable salt thereof, wherein R is ##STR2## R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are H, alkyl or alkoxyalkyl; R.sup.6 is H, alkyl, hydroxyalkyl or --CH.sub.2 F; R.sup.7, R.sup.8 and R.sup.9 are H










 
 
  Recently Added Patents
Tuning peg for a stringed instrument
Signal processing apparatus and methods
Printing apparatus having extendable functionality and method thereof
Video-recording reservation management apparatus, method, program, and system
Method and system to generate finite state grammars using sample phrases
Automated incorporation of expert feedback into a monitoring system
Strap-hook ring
  Randomly Featured Patents
Printing apparatus, method for controlling print job, and computer program for pre-registering condition information relating to conditions for cancelling execution of a print job
Uninterrupted power system with frequency and phase control
In-die cover forming method and method for manufacturing product integrated with cover
Halogen incandescent lamp having a socket
Full reversing hydromechanical steering transmission with multi-range synchronous shifting concentric gear train package
Rim microcellular polyurethane elastomer employing heteric or internal block ethylene oxide polyols
Fastening apparatus
First and second derivative processing of wavelength multiplexed optical signals
Stereophonic device for headphones and audio signal processing program
Ornamental element mounting means